

# Charles Marie Dumontet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8078973/publications.pdf>

Version: 2024-02-01

273  
papers

19,950  
citations

18887

64  
h-index

14012

133  
g-index

285  
all docs

285  
docs citations

285  
times ranked

26550  
citing authors

#	ARTICLE	IF	CITATIONS
1	A polygenic risk score for multiple myeloma risk prediction. <i>European Journal of Human Genetics</i> , 2022, 30, 474-479.	1.4	5
2	Proof of Concept: Protein Delivery into Human Erythrocytes Using Stable Cavitation. <i>Molecular Pharmaceutics</i> , 2022, 19, 929-935.	2.3	4
3	Common gene variants within 3' untranslated regions as modulators of multiple myeloma risk and survival. <i>International Journal of Cancer</i> , 2021, 148, 1887-1894.	2.3	3
4	Enhanced migration of breast and lung cancer cells deficient for cN-II and CD73 via COX-2/PGE2/AKT axis regulation. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 151-165.	2.1	5
5	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. <i>Nature Communications</i> , 2021, 12, 293.	5.8	54
6	Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1/XPF-mediated DNA repair. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 259-267.	1.1	7
7	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. <i>Human Molecular Genetics</i> , 2021, 30, 1142-1153.	1.4	2
8	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , 2021, 149, 327-336.	2.3	3
9	Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. <i>Pharmaceutics</i> , 2021, 14, 247.	1.7	27
10	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021, 11, 74.	2.8	10
11	CD73 and cN-II regulate the cellular response to chemotherapeutic and hypoxic stress in lung adenocarcinoma cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129842.	1.1	4
12	Prognostic impact of cN-III mRNA expression on overall survival and drug sensitivity in pediatric leukemia. <i>Leukemia and Lymphoma</i> , 2021, , 1-6.	0.6	1
13	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 813-824.	5.5	34
14	Transcriptional and Metabolic Investigation in 5' Nucleotidase Deficient Cancer Cell Lines. <i>Cells</i> , 2021, 10, 2918.	1.8	2
15	Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2371-2381.	1.9	3
16	Antibody-Drug Conjugates: The Last Decade. <i>Pharmaceutics</i> , 2020, 13, 245.	1.7	207
17	How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?. <i>Frontiers in Immunology</i> , 2020, 11, 492.	2.2	40
18	Characterization of TDM1-resistant breast cancer cells. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00617.	1.1	9

#	ARTICLE	IF	CITATIONS
19	<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 2422-2432.	3.2	37
20	Targeting the nucleotide metabolism proteins of the NUDIX family and SAMHD1 in cancer. <i>Current Medicinal Chemistry</i> , 2020, 28, 4088-4116.	1.2	2
21	A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. <i>Frontiers in Immunology</i> , 2019, 10, 1943.	2.2	22
22	Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates. <i>Chemical Science</i> , 2019, 10, 4048-4053.	3.7	59
23	The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis?. <i>Leukemia and Lymphoma</i> , 2019, 60, 2572-2575.	0.6	4
24	Exome sequencing identifies germline variants in <i>DIS3</i> in familial multiple myeloma. <i>Leukemia</i> , 2019, 33, 2324-2330.	3.3	33
25	<i>In vitro</i> modulation of multidrug resistance by pregnane steroids and <i>in vivo</i> inhibition of tumour development by 7 $\beta$ -OBz-11 $\beta$ -(R)-OTHP-5 $\beta$ -pregnanedione in K562/R7 and H295R cell xenografts. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 684-691.	2.5	4
26	Lead optimization and biological evaluation of fragment-based cN-II inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 168, 28-44.	2.6	9
27	Engineering therapeutic bispecific antibodies using CrossMab technology. <i>Methods</i> , 2019, 154, 21-31.	1.9	89
28	Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP). <i>Breast Cancer Research</i> , 2019, 21, 7.	2.2	93
29	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1803-1811.	0.6	11
30	Granulocyte Colony-Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part I): Synthesis and Biodistribution Studies. <i>Bioconjugate Chemistry</i> , 2018, 29, 795-803.	1.8	4
31	Granulocyte-Colony Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part II): Dose-Dependent Biodistribution and <i>In Vivo</i> Antitumor Efficacy in Combination with Rituximab. <i>Bioconjugate Chemistry</i> , 2018, 29, 804-812.	1.8	3
32	Germline Lysine-Specific Demethylase 1 ( <i>LSD1/KDM1A</i> ) Mutations Confer Susceptibility to Multiple Myeloma. <i>Cancer Research</i> , 2018, 78, 2747-2759.	0.4	56
33	Functions of the multi-interacting protein <i>KIDINS220/ARMS</i> in cancer and other pathologies. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 114-122.	1.5	8
34	The genomic landscape of plasma cells in systemic light chain amyloidosis. <i>Blood</i> , 2018, 132, 2775-2777.	0.6	12
35	Platelet concentrate supernatants alter endothelial cell mRNA and protein expression patterns as a function of storage length. <i>Transfusion</i> , 2018, 58, 2635-2644.	0.8	11
36	Piperidinyl-embedded chalcones possessing anti <i>PI3K</i> inhibitory properties exhibit anti-atopic properties in preclinical models. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 405-413.	2.6	4

#	ARTICLE	IF	CITATIONS
37	The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. <i>Frontiers in Immunology</i> , 2018, 9, 2100.	2.2	94
38	A predictive model for risk of early grade 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , 2018, 32, 1404-1413.	3.3	53
39	Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells. <i>Pharmacology</i> , 2018, 102, 161-168.	0.9	8
40	Real life management of patients hospitalized with multiple myeloma in France. <i>PLoS ONE</i> , 2018, 13, e0196596.	1.1	8
41	CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 1051-1055.	2.6	24
42	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. <i>PLoS Genetics</i> , 2018, 14, e1007111.	1.5	30
43	Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway. <i>Oncotarget</i> , 2018, 9, 21141-21155.	0.8	17
44	Alteration of Natural Killer cell phenotype and function in obese individuals. <i>Clinical Immunology</i> , 2017, 177, 12-17.	1.4	93
45	Doxorubicin Delivery into Tumor Cells by Stable Cavitation without Contrast Agents. <i>Molecular Pharmaceutics</i> , 2017, 14, 441-447.	2.3	17
46	TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML). <i>Leukemia Research</i> , 2017, 56, 21-28.	0.4	6
47	Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1053, 101-110.	1.2	5
48	Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 498-500.	1.5	3
49	Strategies and challenges for the next generation of antibody-drug conjugates. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 315-337.	21.5	1,527
50	Identification of miRSNPs associated with the risk of multiple myeloma. <i>International Journal of Cancer</i> , 2017, 140, 526-534.	2.3	8
51	Modeling the Colchicum autumnale Tubulin and a Comparison of Its Interaction with Colchicine to Human Tubulin. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1676.	1.8	16
52	Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients. <i>PLoS ONE</i> , 2017, 12, e0170160.	1.1	25
53	High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. <i>World Journal of Stem Cells</i> , 2017, 9, 227-234.	1.3	31
54	The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance. <i>Oncotarget</i> , 2017, 8, 57622-57641.	0.8	135

#	ARTICLE	IF	CITATIONS
55	The cytosolic 5â€²-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 67380-67393.	0.8	13
56	Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). <i>Oncotarget</i> , 2016, 7, 2889-2909.	0.8	19
57	Beta-hydroxyphosphonate ribonucleoside analogues derived from 4-substituted-1,2,3-triazoles as IMP/GMP mimics: synthesis and biological evaluation. <i>Beilstein Journal of Organic Chemistry</i> , 2016, 12, 1476-1486.	1.3	14
58	Stably transfected adherent cancer cell models with decreased expression of 5â€²-nucleotidase cN-II. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2016, 35, 604-612.	0.4	7
59	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 4350-4355.	3.2	38
60	Deoxycholic acid derivatives as inhibitors of P-glycoprotein-mediated multidrug efflux. <i>Steroids</i> , 2016, 116, 5-12.	0.8	9
61	Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents. <i>Journal of Visualized Experiments</i> , 2016, , e53846.	0.2	7
62	A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1890-1899.	1.9	28
63	Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1238-1247.	1.9	11
64	The druggability of intracellular nucleotide-degrading enzymes. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 883-893.	1.1	16
65	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. <i>Oncotarget</i> , 2016, 7, 59029-59048.	0.8	16
66	Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. <i>Breast Cancer Research</i> , 2015, 17, 57.	2.2	93
67	Spatial and Temporal Control of Cavitation Allows High In Vitro Transfection Efficiency in the Absence of Transfection Reagents or Contrast Agents. <i>PLoS ONE</i> , 2015, 10, e0134247.	1.1	19
68	Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, e204-e206.	1.7	14
69	Synthesis of New Steroidal Inhibitors of P-Glycoprotein-Mediated Multidrug Resistance and Biological Evaluation on K562/R7 Erythroleukemia Cells. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1832-1845.	2.9	12
70	Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. <i>MAbs</i> , 2015, 7, 192-198.	2.6	29
71	Determination of the enzymatic activity of cytosolic 5â€²-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 5747-5758.	1.9	20
72	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015, 6, 7539.	5.8	38

#	ARTICLE	IF	CITATIONS
73	Higher percentage of CD34 + CD38 <sup>+</sup> cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 622-629.	0.6	9
74	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. <i>Endocrine-Related Cancer</i> , 2015, 22, 545-559.	1.6	11
75	Identification of Noncompetitive Inhibitors of Cytosolic 5 <sup>α</sup> -Nucleotidase II Using a Fragment-Based Approach. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9680-9696.	2.9	18
76	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. <i>International Journal of Cancer</i> , 2015, 136, E351-8.	2.3	30
77	Cytosolic 5 <sup>α</sup> -Nucleotidase II Interacts with the Leucine Rich Repeat of NLR Family Member Ipaf. <i>PLoS ONE</i> , 2015, 10, e0121525.	1.1	17
78	Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. <i>PLoS ONE</i> , 2015, 10, e0136505.	1.1	6
79	Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 855-862.	0.6	16
80	2-[18F]Fludarabine, a Novel Positron Emission Tomography (PET) Tracer for Imaging Lymphoma: a Micro-PET Study in Murine Models. <i>Molecular Imaging and Biology</i> , 2014, 16, 118-126.	1.3	14
81	Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 670-674.	1.1	13
82	Structure-activity relationships of $\beta$ -hydroxyphosphonate nucleoside analogues as cytosolic 5 <sup>α</sup> -nucleotidase II potential inhibitors: Synthesis, in vitro evaluation and molecular modeling studies. <i>European Journal of Medicinal Chemistry</i> , 2014, 77, 18-37.	2.6	21
83	Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 817-824.	0.9	7
84	SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2014, 20, 4574-4583.	3.2	258
85	Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. <i>Leukemia and Lymphoma</i> , 2014, 55, 188-190.	0.6	11
86	Fully validated assay for the quantification of endogenous nucleoside mono- and triphosphates using online extraction coupled with liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 2925-2941.	1.9	32
87	In vitro antileukaemic activity of extracts from <i>Daphne gnidium</i> leaves against sensitive and multidrug resistant K562/R7 cells. <i>Tumor Biology</i> , 2014, 35, 8991-8998.	0.8	6
88	Localization of putative binding sites for cyclic guanosine monophosphate and the anti-cancer drug 5-fluoro-2 <sup>α</sup> -deoxyuridine-5 <sup>α</sup> -monophosphate on ABCC11 in silico models. <i>BMC Structural Biology</i> , 2013, 13, 7.	2.3	11
89	Identification and characterization of inhibitors of cytoplasmic 5 <sup>α</sup> -nucleotidase cN-II issued from virtual screening. <i>Biochemical Pharmacology</i> , 2013, 85, 497-506.	2.0	29
90	Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium. <i>Journal of Human Genetics</i> , 2013, 58, 155-159.	1.1	5

#	ARTICLE	IF	CITATIONS
91	Bortezomib influences the expression of malignant plasma cells membrane antigens. <i>European Journal of Pharmacology</i> , 2013, 706, 11-16.	1.7	12
92	3- <i>Aryl</i> -4-methyl-2-quinolones Targeting Multiresistant <i>Staphylococcus aureus</i> Bacteria. <i>ChemMedChem</i> , 2013, 8, 652-657.	1.6	32
93	Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 447-464.	21.5	925
94	Small Molecule Inhibitors of ERCC1-XPF Protein-Protein Interaction Synergize Alkylating Agents in Cancer Cells. <i>Molecular Pharmacology</i> , 2013, 84, 12-24.	1.0	80
95	Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?. <i>Biomarkers in Medicine</i> , 2013, 7, 663-671.	0.6	16
96	Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors. <i>Clinical Cancer Research</i> , 2013, 19, 3556-3566.	3.2	14
97	Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2031-2042.	1.9	301
98	Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. <i>Prostate</i> , 2013, 73, 1738-1746.	1.2	31
99	Resistance to Anticancer Antibodies: From Mechanisms to Solutions. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , 1-24.	0.1	0
100	Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1782-1791.	13.9	1,022
101	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. <i>British Journal of Haematology</i> , 2012, 158, 805-809.	1.2	19
102	Virtual Screening and Biological Evaluation of Inhibitors Targeting the XPA-ERCC1 Interaction. <i>PLoS ONE</i> , 2012, 7, e51329.	1.1	60
103	A label-free mass spectrometry method for relative quantitation of $\beta$ -tubulin isotype expression in human tumor tissue. <i>Proteomics - Clinical Applications</i> , 2012, 6, 502-506.	0.8	4
104	Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma. <i>Gastroenterology</i> , 2012, 143, 664-674.e6.	0.6	218
105	Gemcitabine is active against clinical multiresistant <i>Staphylococcus aureus</i> strains and is synergistic with gentamicin. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 444-447.	1.1	34
106	Progesterone-adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux: Design, synthesis, characterization and biological evaluation. <i>Steroids</i> , 2012, 77, 1177-1191.	0.8	8
107	Le microbiome intestinal influence-t-il le d�veloppement des h�patocarcinomes ?. <i>Bulletin Du Cancer</i> , 2012, 99, 1105-1106.	0.6	0
108	Synthesis and Evaluation of a Molecularly Imprinted Polymer for Selective Solid-Phase Extraction of Irinotecan from Human Serum Samples. <i>Journal of Functional Biomaterials</i> , 2012, 3, 131-142.	1.8	8



#	ARTICLE	IF	CITATIONS
109	Pharmacological Inhibition of LIM Kinase Stabilizes Microtubules and Inhibits Neoplastic Growth. <i>Cancer Research</i> , 2012, 72, 4429-4439.	0.4	67
110	Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. <i>Investigational New Drugs</i> , 2012, 30, 1121-1131.	1.2	105
111	Prognostic value of PINI index in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2012, 88, 306-313.	1.1	22
112	Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMME-SE consortium. <i>British Journal of Haematology</i> , 2012, 157, 331-338.	1.2	13
113	Leukocytosis and Circulating Blasts in Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Are They Valuable Factors for Therapeutic Decision-Making?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 342-349.	0.2	9
114	The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. <i>Lancet Oncology</i> , The, 2011, 12, 693-702.	5.1	147
115	Hybrid Model of Erythropoiesis and Leukemia Treatment with Cytosine Arabinoside. <i>SIAM Journal on Applied Mathematics</i> , 2011, 71, 2246-2268.	0.8	24
116	Les anticorps thérapeutiques spécifiques : deux fois plus puissants ?. <i>Bulletin Du Cancer</i> , 2011, 98, 1381-1382.	0.6	0
117	Inhibition of IGF-1 Signalling Enhances the Apoptotic Effect of AS602868, an IKK2 Inhibitor, in Multiple Myeloma Cell Lines. <i>PLoS ONE</i> , 2011, 6, e22641.	1.1	18
118	Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 1673-1676.	0.6	51
119	Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMME-SE consortium (Review). <i>International Journal of Oncology</i> , 2011, 40, 625-38.	1.4	14
120	Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells. <i>Oncology Reports</i> , 2011, 25, 1161-7.	1.2	9
121	Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 97-105.	1.1	4
122	Minimally differentiated acute myeloid leukemia (FAB AML-M0): Prognostic factors and treatment effects on survival – A retrospective study of 42 adult cases. <i>Leukemia Research</i> , 2011, 35, 1027-1031.	0.4	7
123	Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 178-185.	1.9	125
124	Silencing of <i>Tubulin Binding Cofactor C</i> Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 303-312.	1.9	10
125	MRP8/ABCC11 Expression Is Regulated by Dexamethasone in Breast Cancer Cells and Is Associated to Progesterone Receptor Status in Breast Tumors. <i>International Journal of Breast Cancer</i> , 2011, 2011, 1-6.	0.6	6
126	Structural Insights into the Inhibition of Cytosolic 5'-Nucleotidase II (cN-II) by Ribonucleoside 5'-Monophosphate Analogues. <i>PLoS Computational Biology</i> , 2011, 7, e1002295.	1.5	24



#	ARTICLE	IF	CITATIONS
127	Multidrug Resistance ABC Transporter Structure Predictions by Homology Modeling Approaches. <i>Current Drug Metabolism</i> , 2011, 12, 268-277.	0.7	13
128	Transfection of cells in suspension by ultrasound cavitation. <i>Journal of Controlled Release</i> , 2010, 142, 251-258.	4.8	43
129	Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells. <i>BMC Cancer</i> , 2010, 10, 135.	1.1	23
130	Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. <i>International Journal of Cancer</i> , 2010, 126, 545-562.	2.3	110
131	Liquid chromatographic methods for the determination of endogenous nucleotides and nucleotide analogs used in cancer therapy: A review. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 1912-1928.	1.2	49
132	Design, synthesis and evaluation of progesterone-adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3165-3168.	1.0	6
133	Primary cutaneous marginal zone lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 156-162.	2.0	37
134	Microtubule-binding agents: a dynamic field of cancer therapeutics. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 790-803.	21.5	1,431
135	BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 3988-3997.	3.2	37
136	The role of $\beta$ III tubulin in predicting chemoresistance in non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 67, 136-143.	0.9	71
137	Potent and Fully Noncompetitive Peptidomimetic Inhibitor of Multidrug Resistance P-Glycoprotein. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6720-6729.	2.9	26
138	Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. <i>Bone Marrow Transplantation</i> , 2010, 45, 1316-1324.	1.3	38
139	Beta-tubulin III expression in prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2010, 44, 371-377.	1.4	16
140	Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 661-665.	0.9	13
141	Dysregulation of Ribosome Biogenesis and Translational Capacity Is Associated with Tumor Progression of Human Breast Cancer Cells. <i>PLoS ONE</i> , 2009, 4, e7147.	1.1	198
142	ADP Ribosylation Factor Like 2 (Arl2) Regulates Breast Tumor Aggressivity in Immunodeficient Mice. <i>PLoS ONE</i> , 2009, 4, e7478.	1.1	22
143	Ixabepilone: targeting $\beta$ III-tubulin expression in taxane-resistant malignancies. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 17-25.	1.9	109
144	Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2780-2790.	1.9	152

#	ARTICLE	IF	CITATIONS
145	Reply to L.C. Panasci. <i>Journal of Clinical Oncology</i> , 2009, 27, e112-e113.	0.8	0
146	Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. <i>Journal of Molecular Endocrinology</i> , 2009, 42, 87-103.	1.1	65
147	Understanding and circumventing resistance to anticancer monoclonal antibodies. <i>MAbs</i> , 2009, 1, 222-229.	2.6	47
148	Bacterial Deoxyribonucleoside Kinases are Poor Suicide Genes in Mammalian Cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2009, 28, 1068-1075.	0.4	2
149	Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 1168-1176.	0.8	461
150	Reply to R.S. Mehta et al. <i>Journal of Clinical Oncology</i> , 2009, 27, 3068-3069.	0.8	1
151	<i>In vivo</i> Model of Follicular Lymphoma Resistant to Rituximab. <i>Clinical Cancer Research</i> , 2009, 15, 851-857.	3.2	36
152	Selective modulation of P-glycoprotein activity by steroidal saponines from <i>Paris polyphylla</i> . <i>FÄ-toterapÄ-Äç</i> , 2009, 80, 39-42.	1.1	34
153	Î³-Tubulin is induced by estradiol in human breast carcinoma cells through an estrogen receptor dependent pathway. <i>Cytoskeleton</i> , 2009, 66, 378-388.	4.4	23
154	Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. class III Î³-tubulin. <i>Journal of Cellular Physiology</i> , 2009, 221, 505-513.	2.0	59
155	Inclusion complexes of a nucleotide analogue with hydroxypropyl-beta-cyclodextrin. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2009, 63, 11-16.	1.6	6
156	Development of a sensitive and selective LC/MS/MS method for the simultaneous determination of intracellular 1-beta-d-arabinofuranosylcytosine triphosphate (araCTP), cytidine triphosphate (CTP) and deoxycytidine triphosphate (dCTP) in a human follicular lymphoma cell line. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1417-1425.	1.2	32
157	Simultaneous quantification of 5-FU, 5-FUrd, 5-FdUrd, 5-FdUMP, dUMP and TMP in cultured cell models by LC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 2937-2944.	1.2	33
158	Simultaneous analysis of eight nucleoside triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3831-3840.	1.2	65
159	Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. <i>Journal of Molecular Graphics and Modelling</i> , 2009, 28, 113-130.	1.3	36
160	Special feature of mixed phosphotriester derivatives of cytarabine. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6340-6347.	1.4	28
161	Severe autoimmune cytopenias in treatment-naïve hepatitis C virus infection: clinical description of 16 cases. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 245-253.	0.8	22
162	Preparation, Characterization and <i>In Vitro</i> ; Evaluation of a New Nucleotide Analogue Prodrug Cyclodextrin Inclusion Complexes. <i>Journal of Nanoscience and Nanotechnology</i> , 2009, 9, 295-300.	0.9	2

#	ARTICLE	IF	CITATIONS
163	Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia. <i>Cancer</i> , 2008, 112, 572-580.	2.0	42
164	Antimitotic and Antiproliferative Activities of Chalcones: Forward Structure-Activity Relationship. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2307-2310.	2.9	166
165	mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene expression levels. <i>Cancer Science</i> , 2008, 99, 1992-2003.	1.7	66
166	High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2008, 143, 54-59.	1.2	18
167	ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor $\beta$ expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. <i>Endocrine-Related Cancer</i> , 2008, 15, 125-138.	1.6	30
168	Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 375, 308-314.	1.0	42
169	Expression of excision repair cross-complementation group 1 and class III $\beta$ -tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 62, 105-112.	0.9	40
170	Is class III $\beta$ -tubulin a predictive factor in patients receiving tubulin-binding agents?. <i>Lancet Oncology</i> , 2008, 9, 168-175.	5.1	275
171	Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience. <i>Clinical Leukemia</i> , 2008, 2, 198-204.	0.2	11
172	Paclitaxel-Loaded Microparticles for Intratumoral Administration via the TMT Technique: Preparation, Characterization, and Preliminary Antitumoral Evaluation. <i>Drug Development and Industrial Pharmacy</i> , 2008, 34, 698-707.	0.9	22
173	Class III $\beta$ -Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel. <i>Clinical Cancer Research</i> , 2008, 14, 4511-4516.	3.2	58
174	Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line. <i>Cell Cycle</i> , 2008, 7, 3074-3082.	1.3	27
175	BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. <i>Blood</i> , 2008, 112, 3154-3163.	0.6	47
176	Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice. <i>Blood</i> , 2008, 112, 1585-1585.	0.6	8
177	Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. <i>Anticancer Research</i> , 2008, 28, 1161-7.	0.5	17
178	Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 708-715.	0.6	81
179	Class III $\beta$ -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10. <i>Clinical Cancer Research</i> , 2007, 13, 994-999.	3.2	138
180	Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. <i>Blood</i> , 2007, 109, 3489-3495.	0.6	845

#	ARTICLE	IF	CITATIONS
181	A revised nomenclature for the human and rodent $\beta$ -tubulin gene family. <i>Genomics</i> , 2007, 90, 285-289.	1.3	60
182	Sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis by hyperthermia. <i>Cancer Letters</i> , 2007, 250, 117-127.	3.2	15
183	Nucleoside analogue delivery systems in cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2007, 4, 513-531.	2.4	23
184	The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. <i>Cancer</i> , 2007, 109, 292-299.	2.0	136
185	Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2007, 1776, 138-159.	3.3	46
186	ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells. <i>Experimental Cell Research</i> , 2007, 313, 473-485.	1.2	33
187	Class III $\beta$ -tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 27-34.	1.1	45
188	Structure-activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 6979-6987.	1.4	54
189	Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. <i>Blood</i> , 2006, 108, 3289-3294.	0.6	639
190	Recent Developments to Improve the Efficacy of Cytotoxic Nucleoside Analogues. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 163-170.	0.8	22
191	Inhibition of P-glycoprotein-mediated multidrug efflux by aminomethylene and ketomethylene analogs of reversins. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5700-5703.	1.0	12
192	F-ara-AMP is a substrate of cytoplasmic 5'-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2006, 25, 289-297.	0.4	13
193	Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 547-554.	1.1	33
194	The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site. <i>Cancer</i> , 2006, 106, 2058-2066.	2.0	51
195	Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. <i>Cancer</i> , 2006, 107, 2698-2705.	2.0	100
196	A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. <i>International Journal of Cancer</i> , 2006, 119, 60-66.	2.3	10
197	Ungueotropic T-Cell Lymphoma. <i>Archives of Dermatology</i> , 2006, 142, 1065.	1.7	13
198	A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma. <i>Bulletin Du Cancer</i> , 2006, 93, E115-8.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Unusual Organisms in the Bone Marrow of a Patient With Systemic Sarcoidosis. <i>Laboratory Medicine</i> , 2005, 36, 762-763.	0.8	0
200	Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. <i>Blood</i> , 2005, 105, 767-774.	0.6	70
201	Chemoresistance in Non-Small Cell Lung Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2005, 5, 73-88.	7.0	129
202	Expression of Class III $\beta$ -Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 5481-5486.	3.2	193
203	Class III $\beta$ -tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 2001-2007.	1.9	224
204	Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1268-1276.	1.9	57
205	Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). <i>Leukemia and Lymphoma</i> , 2005, 46, 335-346.	0.6	18
206	cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 49, 363-370.	0.9	62
207	Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. <i>Bulletin Du Cancer</i> , 2005, 92, E25-30.	0.6	42
208	The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. <i>Haematologica</i> , 2005, 90, 1699-701.	1.7	34
209	Structure-Activity Relationships for Euphocharacins A - L, a New Series of Jatrophone Diterpenes, as Inhibitors of Cancer Cell P-Glycoprotein. <i>Planta Medica</i> , 2004, 70, 657-665.	0.7	34
210	Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line. <i>Clinical Cancer Research</i> , 2004, 10, 5614-5621.	3.2	60
211	The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6956-6961.	3.2	360
212	Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma. <i>The Hematology Journal</i> , 2004, 5, 403-409.	2.0	11
213	Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia. <i>Oncogene</i> , 2004, 23, 2287-2297.	2.6	26
214	Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. <i>BMC Pharmacology</i> , 2004, 4, 8.	0.4	62
215	Problems Related to Resistance to Cytarabine in Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 1123-1132.	0.6	60
216	Maintenance Therapy with a Monthly Injection of Alemtuzumab Prolongs Response Duration in Patients with Refractory B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL). <i>Leukemia and Lymphoma</i> , 2004, 45, 711-714.	0.6	29

#	ARTICLE	IF	CITATIONS
217	Jatrophane Diterpenes as Modulators of Multidrug Resistance. Advances of Structure-Activity Relationships and Discovery of the Potent Lead Pepluanin A. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 988-992.	2.9	87
218	Antimitotic Activity of 5-Hydroxy-7-methoxy-2-phenyl-4-quinolones. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4964-4970.	2.9	65
219	Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1361-1365.	0.8	27
220	5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine. <i>Haematologica</i> , 2004, 89, 617-9.	1.7	8
221	In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine. <i>Biochemical Pharmacology</i> , 2003, 66, 2185-2191.	2.0	24
222	Influence of p53 and p21WAF1 expression on sensitivity of cancer cells to cladribine. <i>Biochemical Pharmacology</i> , 2003, 65, 121-129.	2.0	22
223	Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue. <i>International Journal of Cancer</i> , 2003, 107, 149-154.	2.3	20
224	Modified jatrophane diterpenes as modulators of multidrug resistance from <i>Euphorbia dendroides</i> L.. <i>Biorganic and Medicinal Chemistry</i> , 2003, 11, 5221-5227.	1.4	36
225	Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. <i>British Journal of Haematology</i> , 2003, 122, 53-60.	1.2	83
226	A New P-Glycoprotein Inhibitor from the Caper Spurge ( <i>Euphorbia lathyris</i> ). <i>Journal of Natural Products</i> , 2003, 66, 140-142.	1.5	57
227	Pyrimidine nucleoside analogs in cancer treatment. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 717-728.	1.1	51
228	Jatrophane Diterpenes as P-Glycoprotein Inhibitors. First Insights of Structure-Activity Relationships and Discovery of a New, Powerful Lead. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3395-3402.	2.9	79
229	Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001. <i>Leukemia and Lymphoma</i> , 2003, 44, 257-262.	0.6	29
230	Role of IMP-SELECTIVE 5-NUCLEOTIDASE (cN-II) in HEMATOLOGICAL MALIGNANCIES. <i>Leukemia and Lymphoma</i> , 2003, 44, 1105-1111.	0.6	28
231	Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. <i>Annals of Oncology</i> , 2003, 14, 615-622.	0.6	8
232	A Two-complementary Method Assay for Screening New Reversal Agents of Cancer Cell Multidrug Resistance. <i>Pharmaceutical Biology</i> , 2003, 41, 72-77.	1.3	2
233	In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene. <i>Blood</i> , 2003, 102, 1549-1550.	0.6	49
234	Microtubule-Associated Parameters as Predictive Markers of Docetaxel Activity in Advanced Breast Cancer Patients: Results of a Pilot Study. <i>Clinical Breast Cancer</i> , 2002, 3, 341-345.	1.1	74



#	ARTICLE	IF	CITATIONS
235	Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 Patients. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 41-47.	2.1	148
236	Nucleoside analogues and nucleobases in cancer treatment. <i>Lancet Oncology</i> , The, 2002, 3, 415-424.	5.1	494
237	Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. <i>Medicinal Research Reviews</i> , 2002, 22, 512-529.	5.0	158
238	Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. <i>International Journal of Cancer</i> , 2002, 97, 439-445.	2.3	92
239	Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. <i>Genes To Cells</i> , 2002, 7, 29-39.	0.5	76
240	In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2002, 117, 860-868.	1.2	144
241	Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. <i>British Journal of Haematology</i> , 2002, 118, 210-217.	1.2	25
242	Potential mechanisms of resistance to cytarabine in AML patients. <i>Leukemia Research</i> , 2002, 26, 621-629.	0.4	125
243	Isoprenoid flavonoids are new leads in the modulation of chemoresistance. <i>Phytochemistry Reviews</i> , 2002, 1, 325-332.	3.1	19
244	Recent Advances in the Discovery of Flavonoids and Analogues with High Affinity Binding to P-Glycoprotein Responsible for Cancer Cell Multidrug Resistance. <i>ChemInform</i> , 2002, 33, 257-257.	0.1	1
245	Thalidomide in patients with advanced multiple myeloma: a study of 83 patients—report of the intergroupe francophone du myélome (IFM). <i>The Hematology Journal</i> , 2002, 3, 185-192.	2.0	71
246	C-Isoprenylation of Flavonoids Enhances Binding Affinity toward P-Glycoprotein and Modulation of Cancer Cell Chemoresistance. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 763-768.	2.9	108
247	Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. <i>Blood</i> , 2001, 98, 1922-1926.	0.6	80
248	The superoxide dismutase content in erythrocytes predicts short-term toxicity of high-dose cyclophosphamide. <i>British Journal of Haematology</i> , 2001, 112, 405-409.	1.2	28
249	Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 113, 772-778.	1.2	90
250	Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. <i>Blood</i> , 2000, 95, 802-806.	0.6	484
251	Mechanisms of action and resistance to tubulin-binding agents. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 779-788.	1.9	39
252	Thalidomide in patients with advanced multiple myeloma. <i>The Hematology Journal</i> , 2000, 1, 186-189.	2.0	32



#	ARTICLE	IF	CITATIONS
253	Transient Acute Myopia Induced by Antilymphocyte Globulins. <i>Ophthalmologica</i> , 1999, 213, 133-134.	1.0	10
254	Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 335-341.	0.5	96
255	Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. <i>British Journal of Haematology</i> , 1999, 106, 78-85.	1.2	125
256	Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. <i>American Journal of Medicine</i> , 1999, 106, 191-197.	0.6	45
257	Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death. <i>Journal of Clinical Oncology</i> , 1999, 17, 1061-1061.	0.8	524
258	Common Resistance Mechanisms to Nucleoside Analogues in Variants of the Human Erythroleukemic Line K562. <i>Advances in Experimental Medicine and Biology</i> , 1999, 457, 571-577.	0.8	12
259	Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. <i>British Journal of Haematology</i> , 1998, 103, 235-241.	1.2	144
260	High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation. <i>Blood</i> , 1998, 91, 3148-3155.	0.6	186
261	Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins. <i>Journal of Biological Chemistry</i> , 1997, 272, 5974-5982.	1.6	74
262	Very low density lipoproteins and interleukin 2 enhance the immunogenicity of 9-O-acetyl-GD3 ganglioside in BALB/c mice. <i>Journal of Immunological Methods</i> , 1997, 206, 115-123.	0.6	9
263	Differential expression of tubulin isotypes during the cell cycle. , 1996, 35, 49-58.		29
264	Early Diagnosis of Ventilator-Associated Pneumonia. <i>Chest</i> , 1996, 110, 1558-1565.	0.4	49
265	IL-3 increases marrow and peripheral erythroid precursors in chronic pure red cell aplasia presenting in childhood. <i>British Journal of Haematology</i> , 1995, 89, 413-416.	1.2	8
266	Decreased Mutation Rate for Cellular Resistance to Doxorubicin and Suppression of mdrl Gene Activation by the Cyclosporin PSC 833. <i>Journal of the National Cancer Institute</i> , 1995, 87, 1593-1602.	3.0	80
267	Inhibition of immune cell proliferation and cytokine production by lipoprotein-bound gangliosides. <i>Cancer Immunology, Immunotherapy</i> , 1994, 38, 311-316.	2.0	19
268	Benign recurrent cholestasis with normal gamma-glutamyl-transpeptidase activity. <i>Journal of Pediatrics</i> , 1992, 121, 78-80.	0.9	16
269	Kinetics and organ distribution of [14C]-sialic acid-GM3 and [3H]-sphingosine-GM1 after intravenous injection in rats. <i>Biochemical and Biophysical Research Communications</i> , 1992, 189, 1410-1416.	1.0	17
270	Silicosis due to inhalation of domestic cleaning powder. <i>Lancet, The</i> , 1991, 338, 1085.	6.3	18

#	ARTICLE	IF	CITATIONS
271	Acute Silicosis Due to Inhalation of a Domestic Product. The American Review of Respiratory Disease, 1991, 143, 880-882.	2.9	24
272	Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. American Journal of Medicine, 1990, 88, 13-20.	0.6	67
273	Human T-cell leukemia virus type I-induced proliferation of human thymocytes requires the presence of a comitogen. Cellular Immunology, 1988, 112, 391-401.	1.4	6